Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 72,534 Shares

Posted by Francis Steltz on Jun 11th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Stephen Bloch sold 72,534 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $64.38, for a total transaction of $4,669,738.92. Following the sale, the director directly owned 1,564,407 shares of the company’s stock, valued at approximately $100,716,522.66. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Liquidia Stock Up 1.9%

Shares of Liquidia stock opened at $65.25 on Thursday. The company has a fifty day moving average price of $48.50 and a 200 day moving average price of $40.37. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $66.78. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of 466.10 and a beta of 0.58.

Liquidia (NASDAQ:LQDA – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia’s revenue for the quarter was up 4187.1% on a year-over-year basis. Equities research analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on LQDA shares. BTIG Research upped their price target on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Wells Fargo & Company upped their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research report on Friday, June 5th. HC Wainwright upped their price objective on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, June 5th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday, May 11th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.29.

Check Out Our Latest Report on Liquidia

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. purchased a new position in Liquidia in the 4th quarter valued at about $25,000. Covestor Ltd boosted its position in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares during the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in Liquidia in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Liquidia in the 3rd quarter valued at about $34,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Liquidia in the 2nd quarter valued at about $25,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).